过去 20 年来，多种创新疗法被应用于肺癌治疗，并在临床试验中报告了生存获益。这些改进是否会转化为临床环境尚未得到研究。我们回顾性分析了在居里研究所连续接受治疗的所有转移性肺癌患者。根据一线新治疗策略的批准情况，使用诊断日期定义三个时期，包括 2010 年的靶向治疗和 2018 年的免疫治疗。终点包括总生存期 (OS)、2 年生存率和 5 年生存率，以及 2 年的条件生存率（如果治疗开始后 6 个月仍存活）。 2000 年至 2009 年第 1 期共确定了 673 名患者，2010 年至 2017 年第 2 期共确定了 752 名患者，2018 年至 2020 年第 3 期共确定了 768 名患者。整个队列的中位 OS 分别为 11.1、15.5 和 16.2 个月。 NSCLC 或 SCLC 患者的中位 OS 分别为 11.2、17.2 和 18.2 个月，或 10.9、11.7 和 11.2 个月。 NSCLC 患者的两年条件生存率优于 SCLC 患者。在所有时期和所有亚组中，女性的结果均高于男性。过去 20 年来，随着新治疗策略的实施，转移性肺癌患者（主要是非小细胞肺癌）的生存率有所提高。

Over the past 20 years, several innovative therapies have been implemented in the treatment of lung cancer that have had reported survival benefits in clinical trials. Whether these improvements translate into the clinic setting has not been studied yet. We retrospectively analyzed all patients consecutively treated at Institute Curie for metastatic lung cancer. Diagnosis date was used to define three periods, based on the approvals of novel treatment strategies in the first-line setting, including targeted therapies in 2010 and immunotherapy in 2018. Endpoints included Overall survival (OS), survival rate of 2 years and 5 years, and a conditional survival rate of 2 years (if still alive at 6 months from treatment initiation). A total of 673 patients were identified for Period 1-2000 to 2009, 752 for Period 2-2010 to 2017, and 768 for Period 3-2018 to 2020. Median OS in the whole cohort was 11.1, 15.5, and 16.2 months, respectively. Median OS for patients with NSCLC or SCLC was 11.2, 17.2, and 18.2 months, or 10.9, 11.7, and 11.2 months, respectively. The two-year conditional survival was more favorable for NSCLC than SCLC patients. Outcomes were statistically higher for women as compared to men in all periods and all subgroups. Survival of patients with metastatic lung cancer has improved over the past 20 years, mostly in NSCLC, along with the implementation of novel treatment strategies.